Tinnitus is on the rise in the Netherlands, but a new proven treatment method now available in the Netherlands offers hope.
- Lenire tinnitus treatment device is now available in HearConsult Utrecht and Mijdrecht.
- 91% of compliant patients reported long-lasting relief from tinnitus that sustained for at least 1-year in a large-scale clinical trial.1
- 91.5% of tinnitus patients reported significant relief from tinnitus in a peer-reviewed analysis of patients treated with Lenire at an independent clinic.2
- Tinnitus affects over 2 million adults in The Netherlands3, with reports suggesting incidences of tinnitus have increased by 33% between 2012 and 2021.4
Utrecht, The Netherlands – February 26, 2026: Neuromod Devices, the medical technology company that specialises in tinnitus treatment technology, has partnered with HearConsult to make the Lenire tinnitus treatment device available in The Netherlands.
Lenire® is a groundbreaking bimodal neuromodulation device that has been proven to provide clinically significant relief from tinnitus across multiple clinical trials and with real-world patients 1,2,5
Tinnitus, which is commonly known as ringing, hissing, or buzzing in the ears, affects over 2 million adults in the Netherlands.3 A recently published paper identified that incidences of tinnitus in the Netherlands have increased by 33% between 2012 and 20214, attributing the increase to loud music exposure, noise pollution, and evolving listening habits. The largest increase was seen in younger adults aged between 20 and 44 years old.
“There has been a significant increase in people whose primary concern is tinnitus in our clinic, and this is common across all Dutch audiology practices,” said Koen Vernooij Au.D., owner of HearConsult. “We have seen the remarkable evidence from clinics across Europe and the United States, and we are excited to make this proven treatment option available at our clinic.”
Lenire Now Available Across Europe and the USA
The Netherlands is the latest country to make Lenire® available, following successful launches in Denmark, Norway, Spain, Italy, Poland, Sweden, Switzerland, and further expansion in the UK.
Utrecht-based researcher, Jan van Dam, spoke about his experience living with tinnitus for decades, and travelling to Belgium for treatment with Lenire prior to the device being made available in the Netherlands:
“As a researcher, I spend quite a lot of time focusing in quiet spaces, and the noise from my tinnitus was very distracting, and it also made socialising difficult,” said Jan van Dam. “I found Lenire’s clinical research compelling, and now, after treating my tinnitus with the device, the tinnitus is much quieter, and it no longer annoys me.”
Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device that has been proven effective in clinical trials and in real-world patient analyses. Lenire’s bimodal neuromodulation combines tongue and auditory stimulation to drive long-term changes in the brain that have been proven to relieve tinnitus severity.
In 2023, Lenire made regulatory history by becoming the first and only bimodal neuromodulation device to be granted De Novo approval by the United States of America Food and Drug Administration (US FDA).
De Novo Approval from the FDA was granted based on the success of Lenire’s TENT-A3 controlled clinical trial. TENT-A3 demonstrated that Lenire was clinically superior for the treatment of tinnitus than sound-therapy, which was the trial’s control.5
Nature – Scientific Reports published results from Lenire’s second large-scale clinical trial, TENT-A2. TENT-A2 showed 95% of compliant patients reported tinnitus improvement. 91% reported long-term relief that sustained for at least a year after treatment ended. 1
Nature Communications Medicine recently published the results of 220 tinnitus patients treated with Lenire in a real-world clinical setting at Alaska Hearing & Tinnitus Center. 91.5% of patients reported clinically meaningful reductions in tinnitus after treatment with Lenire.2
Acknowledging the large evidence-based, Lenire has been rated as the top tinnitus treatment option for safety and effectiveness by the leading tinnitus charity, Tinnitus UK.
Lenire is available in the Netherlands through HearConsult following a suitability assessment.
Tinnitus Information Sessions in Mijdrecht
HearConsult is running 4 information sessions for patients with tinnitus on the 26th and 27th of March in Mijdrecht. There will be 2 sessions per day at 14:00 and 20:00. The sessions will cover the causes of tinnitus and the available treatment options, as well as tips for managing your tinnitus.
Attendance is free, but places are limited and must be reserved in advance at https://www.hearconsult.nl/. Complimentary parking and refreshments provided.
References
- Conlon, B., Hamilton, C., Meade, E., Hall, D. A., Roche, A. J. P., & Lim, H. H. (2022). Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports, 12(1), Article 13875. https://doi.org/10.1038/s41598-022-13875-x
- McMahan, E., & Lim, H. H. (2025). Retrospective chart review demonstrating the effectiveness of bimodal neuromodulation for tinnitus treatment. Communications Medicine, 5(1). [Note: Use specific volume/issue if available upon publication].
- Biswas, R., Lugo, A., Akeroyd, M. A., Gallus, S., & Hall, D. A. (2021). Tinnitus prevalence in Europe: A multi-country cross-sectional population study. The Lancet Regional Health – Europe, 12, Article 100250. https://doi.org/10.1016/j.lanepe.2021.100250
- Bes, J., van Putten, M. J. A. M., Stegeman, I., & Stokroos, R. J. (2024). The impact of tinnitus on Dutch GPs: A retrospective study using routine healthcare data. PLOS ONE, 19(11), Article e0313630. https://doi.org/10.1371/journal.pone.0313630
- Boedts, M., Buechner, A., Khoo, S. G., & Lim, H. H. (2024). Combining sound with tongue stimulation for the treatment of tinnitus: A multi-site single-arm controlled pivotal trial. Nature Communications, 15, Article 999. https://doi.org/10.1038/s41467-024-44851-x
